FDA Grants Breakthrough Therapy Designation to Larimar’s Nomlabofusp—Accelerated Path Toward First Disease-Modifying Friedreich’s Ataxia Treatment
Breakthrough Therapy Designation Marks Significant Progress for Nomlabofusp
Larimar Therapeutics received Breakthrough Therapy Designation (BTD) from the FDA for its lead candidate, nomlabofusp, as a potential treatment for Friedreich’s ataxia (FA)—a rare, debilitating neurodegenerative disorder impacting around 5,000 people in the U.S. The designation follows a review of clinical data from an ongoing open label (OL) study, and signals a big step forward for accelerating nomlabofusp’s development and regulatory review.
Clinical Data Shows Consistent Improvement Across Four Key Disease Outcomes
Nomlabofusp secured its BTD based on preliminary evidence of clinical benefit. The OL study demonstrated:
- Increases in skin frataxin (FXN) levels, bringing patients closer to the levels of asymptomatic carriers.
- Consistent directional improvement after one year of treatment in:
- Modified Friedreich Ataxia Rating Scale (mFARS)
- FARS-Activities of Daily Living (ADL)
- 9 Hole Peg Test (9-HPT)
- Modified Fatigue Impact Scale (MFIS)
| Key Outcome | Observed Trend with Nomlabofusp | Comparator (FACOMS Study) |
|---|---|---|
| Skin FXN Levels | Increased to asymptomatic carrier range | Remains low in untreated FA |
| mFARS Score | Consistent improvement | Progressive worsening |
| ADL, 9-HPT, MFIS | Directional improvements | Progressive worsening |
FDA Feedback Aligns on Accelerated Approval Path, Novel Endpoints, and Global Phase 3 Plans
Larimar and the FDA reached alignment on several key regulatory aspects after a recent START (Support for Clinical Trials Advancing Rare Disease Therapeutics) meeting:
- The FDA is willing to consider skin FXN as a surrogate biomarker likely to predict clinical benefit—a novel approach that could speed up approval.
- The agency encouraged use of matched reference groups from the FACOMS database for clinical comparisons in the Biologics License Application (BLA).
- Agreement that topline OL study data, exposure-response analyses, and confirmatory global Phase 3 trial evidence will support the BLA.
- The primary endpoint for Phase 3 will focus on Upright Stability Score (USS), a clinically relevant subscale of mFARS.
- The adequacy of the safety database will be reviewed at the time of BLA submission.
| Milestone | Expected Date |
|---|---|
| Confirmatory Phase 3 Study Screening | Q2 2026 |
| First Patient Dosed (Phase 3) | Mid-2026 |
| Topline OL Study Data | Q2 2026 |
| BLA Submission (U.S.) | June 2026 |
| Potential U.S. Launch | First half of 2027 |
Potential Impact: First Disease-Modifying Therapy for Friedreich’s Ataxia in Sight
Experts including Dr. Marshall Summar (CEO of Uncommon Cures) describe the clinical gains seen with nomlabofusp as promising for FA patients. As the first therapy targeting the root cause of FA (frataxin deficiency), nomlabofusp could change the clinical landscape if Phase 3 results hold up and regulatory review remains positive.
Key Takeaways—Why This Matters for Patients and Investors
The BTD not only offers expedited review processes but also reflects the FDA’s recognition of nomlabofusp’s potential to meaningfully alter disease progression. For investors and patient advocates, the focus now shifts to upcoming clinical milestones in 2026 and the all-important BLA submission. If successful, Larimar could deliver the first FDA-approved, disease-modifying therapy for Friedreich’s ataxia as early as 2027.
While regulatory hurdles and clinical uncertainties remain, this FDA designation sets a clear, accelerated path forward for Larimar and the rare disease community.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI